Skip to content

Biodesix, Inc. BDSX Accrued Liabilities, Current

Accrued Liabilities, Current at other companies

Veracyte logo
VeracyteVCYT
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
Guardant Health logo
Guardant HealthGH
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
GeneDx Holdings logo
GeneDx HoldingsWGS
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT

Other financials

Income statement

See full
Revenue$25.6M+42.3%
Operating income-$6.2M+32.1%
Net income-$7.8M+29.8%
EPS (diluted)-$0.81+46.7%

Balance sheet

See full
Cash & equivalents$25.6M+45.3%
Total debt$71.6M+15.0%
Total equity$9.1M-17.4%
Total assets$94.6M+9.7%

Cash flow

See full
Operating cash flow-$10.2M-18.2%
CapEx$81.0K+9.5%
Free cash flow-$10.2M-18.1%

Valuation

See full
Market cap$233.52M+476%
Enterprise value$279.56M+204%
P/S2.4×+1.9×

Profitability

See full
Operating margin-26%-7.5pp
Net margin-33.3%-9.3pp
FCF margin-26.8%-9.6pp

Returns & leverage

See full
Return on equity-316.5%
Debt / equity7.8×+2.2×
Current ratio2.8×+0.6×

Where this comes from

Reported directly by Biodesix, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Biodesix, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biodesix, Inc.'s accrued liabilities, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biodesix, Inc.'s accrued liabilities, current?
Biodesix, Inc. (BDSX) reported accrued liabilities, current of $8.23M in Q1 2026.
How has Biodesix, Inc.'s accrued liabilities, current changed year-over-year?
Biodesix, Inc.'s accrued liabilities, current increased by 11.2% year-over-year, from $7.4M to $8.23M.
What is the long-term trend for Biodesix, Inc.'s accrued liabilities, current?
Over 5 years (2020 to 2025), Biodesix, Inc.'s accrued liabilities, current has grown at a 7.2% compound annual growth rate (CAGR), from $7.79M to $11.03M.